Do Disease-Modifying Therapies for Multiple Sclerosis Increase COVID-19 Risk?
Patients with multiple sclerosis do not need to alter their disease-modifying therapy regimen to prevent COVID-19 infection and hospitalization.
Stay updated with breaking news from Multiple Sclerosis Centers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patients with multiple sclerosis do not need to alter their disease-modifying therapy regimen to prevent COVID-19 infection and hospitalization.
Depression and attentional alterations are recurrent in patients with relapsing-remitting MS, with a relationship between depression and sustained attention performance.
Peginterferon beta-1a has a higher rate of treatment adherence and persistence compared to other disease-modifying therapies for multiple sclerosis.
Paleolithic elimination and low-saturated fat diets are associated with improvements in fatigue, cognitive dysfunction, and quality of life in patients with multiple sclerosis, new research suggests.
Most don't ask for medical guidance, survey shows